抗RA33抗体存在于部分免疫检查点抑制剂诱导的炎症性关节炎患者中
本研究用ELISA检测四组患者血清抗RA33抗体:79例ICI诱导的炎症性关节炎(IA)、52例类风湿关节炎(RA)、35例接受ICI治疗但随访期间未发生IA者及50例健康对照。ICI诱导IA组9/79(11.4%)抗RA33阳性,未发生IA的ICI治疗组0/35(0%)(p=0.04)。结论认为抗RA33抗体存在于部分ICI诱导IA患者中,在其他ICI治疗患者中缺失,可能是发生IA的生物标志物。
要点
- ICI诱导IA患者抗RA33阳性率为11.4%(9/79),未发生IA的ICI治疗者为0%(0/35),组间比较p=0.04。
- RA患者抗RA33阳性率为7.7%,健康对照为2%。
- ICI诱导IA中抗RA33抗体与抗CCP抗体相关(p=0.001)。
核心结论
- 抗RA33抗体存在于部分ICI诱导IA患者中,在其他接受ICI治疗的患者中缺失,可能是发生IA的生物标志物。
- 作者认为,需在ICI治疗前后评估系列样本的额外研究来进一步确立这些抗体与IA发生的时间关系。
研究设计与样本
- 对四组患者血清进行抗RA33 ELISA检测:79例ICI诱导IA、52例RA、35例接受ICI治疗但随访期间未发生IA、50例健康对照。
- 比较各组间抗RA33阳性率与水平及临床和人口学数据。
主要发现
- 抗RA33抗体见于9/79(11.4%)ICI诱导IA患者,而接受ICI治疗未发生IA者为0/35(0%)(p=0.04)。
- 抗RA33阳性的ICI诱导IA患者中2例有ICI治疗前血清,两例治疗前均已存在抗RA33抗体。
- RA患者7.7%抗RA33阳性,健康对照2%阳性。
- ICI诱导IA中抗RA33抗体与抗CCP抗体相关(p=0.001)。
- 有无抗RA33抗体的患者在其他临床特征上未见统计学显著差异。
关键数值与推荐
- ICI诱导IA组抗RA33阳性9/79(11.4%),未发生IA的ICI治疗组0/35(0%),p=0.04。
- RA组抗RA33阳性率7.7%,健康对照组2%。
- ICI诱导IA中抗RA33与抗CCP抗体相关,p=0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需在ICI治疗前后评估系列样本的额外研究来进一步确立这些抗体与IA发生的时间关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with inflammatory arthritis (IA) associated with immune checkpoint inhibitor (ICI) treatment for cancer are typically seronegative for anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor, but little is known about the presence of other autoantibodies in this patient population. We investigated the prevalence and characteristics of anti-RA33 antibodies in patients with ICI-induced IA. METHODS: Anti-RA33 ELISAs were performed on sera from four groups of patients: 79 with ICI-induced IA, 52 with rheumatoid arthritis (RA), 35 treated with ICIs without IA during follow-up and 50 healthy controls. Anti-RA33 positivity and level, clinical and demographic data were compared across groups. RESULTS: Anti-RA33 antibodies were found in 9/79 (11.4%) patients with ICI-induced IA but in 0/35 patients treated with ICIs who did not develop IA (0%; p=0.04). Of the patients positive for anti-RA33, two had sera available from before ICI treatment; anti-RA33 antibodies were present in both pre-ICI treatments. In patients with RA, 7.7% were positive for anti-RA33 antibodies as were 2% of healthy controls. In ICI-induced IA, anti-RA33 antibodies were associated with anti-CCP antibodies (p=0.001). We found no statistically significant differences in other clinical characteristics in those with and without anti-RA33 antibodies. CONCLUSIONS: Anti-RA33 antibodies are present in a subset of patients with ICI-induced IA, absent in other ICI-treated patients and may be a biomarker for developing IA. Additional studies evaluating serial samples before and after ICI treatment will further establish the temporal relationship of these antibodies to IA development.
引用
- Cappelli LC, Bingham CO, Forde PM, et al. Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis. RMD Open. 2022. PMID: 36096522. doi:10.1136/rmdopen-2022-002511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。